Complete financial analysis of Senti Biosciences, Inc. (SNTI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Senti Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Oriental Land Co., Ltd. (4661.T) Income Statement Analysis – Financial Results
- Caisse Régionale de Crédit Agricole Mutuel du Languedoc Société coopérative (CRLA.PA) Income Statement Analysis – Financial Results
- Special Opportunities Fund, Inc. (SPE) Income Statement Analysis – Financial Results
- Change Healthcare Inc. (CHNGU) Income Statement Analysis – Financial Results
- Harworth Group plc (HWG.L) Income Statement Analysis – Financial Results
Senti Biosciences, Inc. (SNTI)
About Senti Biosciences, Inc.
Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells in the body. The company was founded in 2016 and is based in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 2.56M | 4.29M | 2.29M | 394.00K | 85.00K |
| Cost of Revenue | 5.24M | 3.92M | 3.01M | 15.96M | 14.52M |
| Gross Profit | -2.68M | 366.00K | -719.00K | -15.56M | -14.44M |
| Gross Profit Ratio | -104.76% | 8.54% | -31.38% | -3,949.75% | -16,987.06% |
| Research & Development | 32.15M | 34.07M | 21.96M | 15.96M | 14.52M |
| General & Administrative | 34.87M | 40.85M | 21.25M | 9.30M | 7.34M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 34.87M | 40.85M | 21.25M | 9.30M | 7.34M |
| Other Expenses | 27.69M | 12.42M | -470.00K | -172.00K | 0.00 |
| Operating Expenses | 95.29M | 74.92M | 42.74M | 25.09M | 7.39M |
| Cost & Expenses | 94.71M | 74.92M | 42.74M | 25.09M | 21.92M |
| Interest Income | 2.86M | 1.70M | 11.00K | 88.00K | 674.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.43M | 3.89M | 3.01M | 1.99M | 427.00K |
| EBITDA | -61.34M | -70.63M | -39.68M | -22.71M | -21.36M |
| EBITDA Ratio | -2,395.00% | -1,647.90% | -1,633.09% | -5,703.30% | -25,123.53% |
| Operating Income | -92.73M | -70.63M | -40.45M | -24.69M | -21.78M |
| Operating Income Ratio | -3,620.73% | -1,647.90% | -1,765.43% | -6,267.51% | -25,625.88% |
| Total Other Income/Expenses | 9.32M | 12.42M | -14.87M | 4.83M | 625.00K |
| Income Before Tax | -83.41M | -58.21M | -55.32M | -19.86M | -21.16M |
| Income Before Tax Ratio | -3,256.77% | -1,358.14% | -2,414.62% | -5,041.12% | -24,890.59% |
| Income Tax Expense | 0.00 | -12.42M | 11.00K | 150.00K | 0.00 |
| Net Income | -92.92M | -58.21M | -55.32M | -19.86M | -21.16M |
| Net Income Ratio | -3,628.23% | -1,358.14% | -2,414.62% | -5,041.12% | -24,890.59% |
| EPS | -16.01 | -22.29 | -12.67 | -4.55 | -1.56 |
| EPS Diluted | -16.01 | -22.29 | -12.67 | -4.55 | -1.56 |
| Weighted Avg Shares Out | 4.44M | 2.61M | 4.37M | 4.37M | 13.59M |
| Weighted Avg Shares Out (Dil) | 4.44M | 2.61M | 4.37M | 4.37M | 13.59M |
Senti Biosciences Announces New Employment Inducement Grants
SNTI Stock Skyrockets on Initial Data From Phase I Cancer Study
Why Is Senti Biosciences Stock Surging Over 400% On Monday?
Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing
Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML
Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights
Senti Bio to Participate in Upcoming Investor Conferences
Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights
Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202
Senti Bio Announces Reverse Stock Split
Source: https://incomestatements.info
Category: Stock Reports